share_log

Vext Announces Financial Results for Q2 2024

Vext Announces Financial Results for Q2 2024

Vext宣布2024年第二季度的财务业绩
newsfile ·  08/20 06:30
  • Revenue of $8.4 million; Adjusted EBITDA1 of $1.1 million.
  • With one of the largest footprints in Ohio amongst publicly traded peers, Vext is well-positioned to grow revenue and cash flow from operations following the August 6th launch of the adult-use program in the state.
  • Vext's Ohio network currently includes a Tier 1 cultivation facility, a manufacturing facility, and two operating retail dispensaries. Upon closing of previously announced acquisitions2 and completion of additional licensing under state law for the Tier 1 cultivation facility, Vext expects reaching the state dispensary license cap in 2024.
  • 营业收入840万美元;调整后的EBITDA1为110万美元。
  • 在公开交易的同行中,维克斯州内覆盖面最大之一,全面考虑到即将于8月6日推出该州的成年人项目,该公司有望增加收入和经营现金流量。
  • 目前,维克斯在俄亥俄州拥有一座一流的种植设施、一座制造设施和两个经营的零售药店。预计在此前宣布的收购完成并完成一级种植设施的额外许可后,维克斯将于2024年达到州药店许可证上限。

Vancouver, British Columbia--(Newsfile Corp. - August 20, 2024) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("VEXT" or the "Company"), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, today reported its financial results for the period ended June 30, 2024. All currency references used in this news release are in U.S. currency unless otherwise noted.

加拿大温哥华--(Newsfile Corp. - 2024年8月20日) - 维克斯科技有限公司 (CSE: VEXT) (OTCQX: VEXTF) ("VEXT"或"公司"),一家总部位于美国的大麻运营商,在亚利桑那州和俄亥俄州都有垂直的业务运营,今天公布了其截至2024年6月30日的财务业绩。本新闻稿中使用的所有货币参考数据均为美元。

Summary Financial Results

财务业绩总结


Q2 2024 Q1 2024 Q2 2023
Revenue $8,426,928 $8,390,023 $9,187,122
EBITDA1 $171,309 ($2,285,845) $2,264,980
Adjusted EBITDA1 $1,084,234 $1,957,074 $1,049,115
Adjusted EBITDA Margin (%)1 12.9% 23.3% 11.4%

2024年第二季度 2024年第一季度 ("Q1 2024") 2023年第二季度
营业收入 $8,426,928 $8,390,023 $9,187,122
EBITDA1 $171,309 ($2,285,845) $2,264,980
调整后的EBITDA1 $1,084,234 $1,957,074 $1,049,115
1.调整后的EBITDA利润率(%) 12.9% 23.3% 11.4%

Management Commentary

管理评论

Eric Offenberger, CEO of Vext, commented, "The launch of adult-use sales in Ohio after quarter-end marks a significant milestone for Vext. Over two years of preparation and operational experience in the state have positioned us well for this transition and we're pleased with the initial results. We view Ohio as one of the most promising adult-use markets in the U.S. and look forward to the opportunities it presents for both the state and Vext."

维克斯的首席执行官埃里克·奥芬伯格(Eric Offenberger)评论道:“8月底结束后的成年人销售启动标志着维克斯的一个重要里程碑。在该州超过两年的准备和运营经验使我们在这个过渡期的位置处于优势,并且我们对初步结果感到满意。我们认为俄亥俄州是美国最有前途的成年人市场之一,并期待它为该州和维克斯带来的机会。”

"The first half of the year continued to present challenges for consumer-facing companies, regardless of sector and geographic concentration. I'm proud of our team's efforts to continue driving traffic in this environment through targeted promotions on a wide range of value-based products. For the remainder of 2024, we anticipate improved performance through our focus on seamlessly transitioning our Ohio dispensaries to serve both medical and adult-use markets, enhancing efficiency in our Arizona operations, and exploring growth opportunities across our footprint, which we expect will lead to increasing cash flow, and solid long-term returns for our shareholders," added Mr. Offenberger.

埃里克·奥芬伯格先生补充说:“今年上半年继续面对着消费者面对的各种挑战,无论是在哪个领域和地理范围内。我为我们的团队在这个环境下通过针对广泛的价值产品的有针对性的促销活动继续推动流量而感到骄傲。在2024年的余下时间里,我们预计将通过重点关注顺利过渡我们的俄亥俄州药店为医疗和成年人市场服务、增强我们亚利桑那州业务的效率和探索我们的业务范围内的增长机会,从而增加现金流量并为我们的股东带来稳健的长期回报。”

Summary of Recent Announcements

最新公告摘要

  • On August 2, 2024, the Company announced that it had secured Certificates of Operation for the dual licensing of its cultivation and manufacturing facility as well as its operated dispensaries in Jackson and Columbus and had received approval from the Ohio Division of Cannabis Control to begin selling adult-use cannabis on Tuesday, August 6, 2024.
  • 2024年8月2日,该公司宣布已获得其种植和制造设施的双重许可证,以及杰克逊和哥伦布的经营药店的许可证,已获得俄亥俄州大麻管制部门的批准,开始在2024年8月6日星期二开始销售成人用大麻。

Vext Announces Board Changes

维克斯公布董事会变更

The Company announced today that Jason Thai Nguyen has stepped down as the Chairman of the Board of Directors (the "Board"), effective August 20, 2024. Mr. Nguyen will retain his position as a Director of Vext. The Company is also pleased to report that the Board has appointed Mark W. Opzoomer, a current independent member of the Board, as non-executive Chairman of the Board, with immediate effect.

该公司今天宣布,Jason Thai Nguyen已于2024年8月20日辞去董事会主席职务。Nguyen先生将继续担任维克斯的董事。同时,该公司还高兴地宣布,董事会已任命董事会独立成员Mark W. Opzoomer为非执行董事会主席,立即生效。

Eric Offenberger, CEO of Vext, noted, "On behalf of Vext and its Board, I would like to thank Thai for his vision, contributions and longstanding commitment during his tenure as Chairman. We are pleased that he will continue to provide his valuable insights as a director. We are equally pleased to have Mark step into the role of Chairman. Having already been a key member of our Board, his deep understanding of our business and dedication to our strategic goals have been evident. I am confident that, under his leadership, Vext will continue to drive shareholder value as we enter the next phase of growth with the launch of adult-use sales in Ohio."

维克斯首席执行官Eric Offenberger指出:“我谨代表维克斯及其董事会,感谢Thai在担任主席期间的远见卓识、贡献和长期承诺。我们很高兴他将继续作为一名董事为我们提供有价值的见解。我们也很高兴Mark接任董事会主席职务。其作为我们董事会的核心成员之一,他对我们业务的深入了解和为我们的战略目标而奋斗的决心显而易见。我相信,在他的领导下,维克斯将在俄亥俄州的成年人销售市场启动的下一阶段继续推动股东价值。”

Q2 2024 Financial Results Conference Call

2024年第二季度财报电话会议

Vext will host a conference call and webcast on Tuesday, August 20, 2024, at 08:00 a.m. ET. to discuss its second quarter 2024 financial results.

维克斯将于2024年8月20日星期二上午08:00举行电话会议和网络直播,讨论其2024年第二季度财务业绩。

Date: August 20, 2024 | Time: 8:00 am E.T.
Participant Dial-in: +1-647-484-8814 or 1-844-763-8274
Replay Dial-in: +1-412-317-0088 or 1-855-669-9658
Conference ID: 10191819
Playback #: 1766292 (Expires on September 3, 2024)

日期:2024年8月20日|时间:上午8:00美国东部时间。
参会拨号:+1-647-484-8814或1-844-763-8274。
重播拨号:+1-412-317-0088或1-855-669-9658。
会议ID:10191819。
播放号码:1766292(有效期为2024年9月3日)。

Listen to webcast:

收听网络直播:

For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com.
Non-IFRS Financial Measures

查看更多详情请浏览Vext的投资者网站或联系投资者关系团队investors@vextscience.com。
非IFRS财务指标

This news release contains certain "non-IFRS financial measures" (equivalent to "non-GAAP financial measures", as such term is defined in National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure ("NI 52-112")), "non-IFRS ratios" (equivalent to "non-GAAP ratios", as such term is defined in NI 52-112), including "EBITDA", "Adjusted EBITDA" and "Adjusted EBITDA margin". These financial measures do not have a standardized definition under IFRS, nor are they calculated or presented in accordance with IFRS and may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. The Company defines "Adjusted EBITDA" as net income (loss) from operations, as reported, before interest and tax, adjusted to exclude extraordinary items, non-recurring items, other non-cash items, including stock-based compensation expense, depreciation and amortization, foreign exchange and acquisition related costs, if applicable. The Company defines "Adjusted EBITDA margin" as Adjusted EBITDA divided by Revenue.

本新闻稿包含某些“非IFRS财务指标”(相当于《52-112号国家仪器——非GAAP和其他财务指标披露》定义下的“非GAAP财务指标”或“非IFRS比率”(相当于NI 52-112下的“非GAAP比率”)),包括“EBITDA”、“调整后的EBITDA”和“调整后的EBITDA利润率”。这些财务指标在IFRS下没有标准化定义,也不是按照IFRS计算或呈现,可能与其他公司呈现的类似指标不可比较。公司将EBITDA定义为利润之前的利息、税、折旧和摊销费用。公司将“调整后的EBITDA”定义为报告的运营净收入(亏损),在利息和税前进行调整,以排除特殊项目、非经常性项目、其他非现金项目(包括股权激励支出、折旧和摊销费用、外汇和收购相关成本等,如果适用的话)。公司将“调整后的EBITDA利润率”定义为调整后的EBITDA除以营业收入。

The Company has provided these financial measures as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. The Company believes that these supplemental financial measures provide a valuable additional measure to use when analyzing the operating performance of the business. These supplemental financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein.

公司提供这些财务指标作为补充信息,并且需要与按照IFRS计算和呈现的财务指标一起考虑。公司认为这些补充财务指标为分析业务运行绩效提供有价值的额外指标。这些补充财务指标不应被视为优越、替代或替代品,只应与此处呈现的IFRS财务指标一起考虑。

The following information provides reconciliations of the non-IFRS financial measures presented herein to the most directly comparable financial measures calculated and presented in accordance with IFRS.

以下信息提供了本文中介绍的非IFRS财务指标与按照IFRS计算和呈现的最直接可比财务指标之间的调节。


Q2 2024 Q1 2024 Q2 2023
Revenue $ 8,426,928 $ 8,390,023 $ 9,187,122
Net Income after taxes $ (4,390,035) $ (6,333,412) $ 535,454
Interest (Net) 801,832 800,680 1,010,812
Income Taxes (127,244) (340,522) (1,141,064)
Depreciation & Amortization 3,886,756 3,587,409 1,859,779
EBITDA $ 171,309 $ (2,285,845) $ 2,264,980
Share-based compensation 233,868 13,065 68,862
Accretion - - (6,004)
Share (Profit) / Loss on JVs 118,370 162,916 13,854
(Gain)/Loss on Asset Disposal - 1,444 -
Refinance of loan payable - - -
Loan costs WPCU loan - - 342
FV of WPCU loan (104,150) 460,870 219,518
Loan costs EWB amortized 44,827 44,286 43,969
FV of APP1803 option - 2,022,211 -
RSU Taxes - 4,199 4,274
Foreign Exchange (910) (559) 310
ERC tax credit - - (1,680,793)
Relative FV adjustment to inventory - - -
Change in FV of Biological 227,503 604,982 119,802
FV increment on acquired inventory sold 393,417 929,505 -
Gain on acquisition of control and bargain purchase - - -
Reserves on Notes Receivable and Investments in Joint Operations - - -
Executive Chairman Severance - - -
Adjusted EBITDA $ 1,084,234 $ 1,957,074 $ 1,049,115
Adjusted EBITDA Margin (%)1 12.9% 23.3% 11.4%

2024年第二季度 2024年第一季度 ("Q1 2024") 2023年第二季度
营业收入 $ 8,426,928 $ 8,390,023 $ 9,187,122
净利润税后 $ (4,390,035) $ (6,333,412) $ 535,454
利息(净) 801,832 800,680 1,010,812
所得税 (127,244) (340,522) (1,141,064)
折旧与摊销 3,886,756 3,587,409 1,859,779
EBITDA $ 171,309 $ (2,285,845) $ 2,264,980
股权酬金 233,868 13,065 68,862
增值 - - (6,004)
股份(利润)/ 损失在合营企业 118,370 162,916 13,854
资产处置的收益/损失 - 1,444 -
偿还应付贷款 - - -
WPCU贷款成本 - - 342
WPCU贷款的公允价值 (104,150) 460,870 219,518
EWB分期摊销的借款成本 44,827 44,286 43,969
APP1803期权的公允价值 - 2,022,211 -
RSU税费 - 4,199 4,274
汇率期货 (910) (559) 310
ERC税收抵免额 - - (1,680,793)
相对于库存的FV调整 - - -
生物板块公允价值变动 227,503 604,982 119,802
销售收购库存增值 393,417 929,505 -
控制权收购收益和商誉溢价 - - -
应收票据和合营企业投资准备金 - - -
执行主席遣散费 - - -
调整后的EBITDA $ 1,084,234 $ 1,957,074 $ 1,049,115
1.调整后的EBITDA利润率(%) 12.9% 23.3% 11.4%

About VEXT Science, Inc.

关于VEXT科技公司

Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio. Vext's expertise spans from cultivation through to retail operations in its key markets. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio, as well as through Vext's partnerships in other states. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations, with the Company having operated profitably since 2016. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value.

Vext Science, Inc.是一家总部位于美国的大麻股运营商,在亚利桑那州和俄亥俄州拥有垂直运营。Vext的专业知识覆盖从种植到在关键市场的零售。总部位于亚利桑那州的Vext拥有和经营先进的种植设施、完全建成的制造设施以及亚利桑那州和俄亥俄州的药房。公司制造Vapen,是亚利桑那州领先的THC浓缩、食品和精馏烟弹品牌之一。该公司的获奖产品系列是由Vext的内部高质量花材创建并在亚利桑那州和俄亥俄州以及Vext在其他州的合作伙伴展开销售。Vext的领导团队具有建立和运营盈利多州业务的实证业绩,该公司自2016年以来一直经营盈利。该公司的主要重点是继续在亚利桑那州和俄亥俄州的核心州增长,汇集尖端科学、制造和营销,为客户提供可靠和有价值的客户体验,同时创造股东价值。

Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at and connect with Vext on Twitter/X and LinkedIn.

Vext Science,Inc。的股票在加拿大证券交易所上市,代码为VEXT,在OTCQX市场上交易,代码为VEXTF。了解更多信息并与Vext在 Twitter/X 和 LinkedIn 上取得联系。

For more details on the Vapen brand:
Vapen website: VapenBrands.com
Instagram: @vapen
Facebook: @vapenbrands

有关Vapen品牌的更多详情,请访问:
Vapen网站: VapenBrands.com
Instagram: @vapen
Facebook:@vapenbrands

Forward Looking Statements

前瞻性声明

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

本新闻稿中的前瞻性声明受到有关Vext在此处和在加拿大证券监管机构的定期文件中披露的具体因素所涉及的各种风险和不确定性的影响。当本新闻稿中使用“将,可能,计划,估计,期望,意图,可以,潜在,相信,应该”和类似表达时,即为前瞻性声明。

Forward-looking statements may include, without limitation, statements regarding future developments and the business and operations of Vext, including but not limited to the Company's transition to serve both the medical and adult-use markets in Ohio and the anticipated results therefrom, market projections of the cannabis industry in the jurisdictions in which the Company operates, statements about the timing and completion of the Ohio Expansion Transaction and the acquisition of additional licenses in Ohio, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at .

前瞻性声明可能包括但不限于关于Vext未来发展和业务的声明,包括但不限于公司在俄亥俄州为医疗和成年人市场服务的转型及预期结果,在公司经营的司法管辖区大麻行业的市场预测,关于俄亥俄州扩张交易和获取更多牌照的计时和完成情况等声明,所有这些声明都受到Vext在SE+系统上的持续披露中包含的风险因素的约束。

Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change.

虽然Vext已试图确定可能导致实际结果、绩效或成就与前瞻性声明不同的重要因素,但还可能存在其他因素导致结果、绩效或成就不如预期、估计或意图,包括但不限于:依赖获得监管批准;从事当前被视为违反美国联邦法律的活动;法律变化;依赖管理;需要额外融资;竞争;由于医用和成年人用大麻行业公众意见和认知不一致,受阻的市场增长和州份采纳;以及监管或政治变化。

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

因为存在这些风险和不确定性,因此这些前瞻性声明中预测的结果或事件可能与实际结果或事件有所不同。因此,读者不应过度依赖前瞻性声明。本新闻稿中的前瞻性声明是在本发布日期做出的。除适用法律要求外,Vext不承担更新或修订此类信息的任何意图或义务,Vext不对此处提及的任何其他公司的披露承担任何责任。

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.

加拿大证券交易所尚未审核、批准或驳回本新闻发布的内容。

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

加拿大证券交易所未审查、批准或驳回本新闻发布内容。

Eric Offenberger
Chief Executive Officer
844-211-3725

Eric Offenberger
首席执行官
844-211-3725

For further information:
Jonathan Ross, Vext Investor Relations
jon.ross@loderockadvisors.com
416-244-9851

有关详细信息:
Jonathan Ross,Vext投资者关系
jon.ross@loderockadvisors.com
416-244-9851

SOURCE: Vext Science, Inc.

来源:Vext科技公司

1 See "Non-IFRS Financial Measures" below for more information regarding Vext's use of non-IFRS financial measures and other reconciliations.

1 有关Vext使用非IFRS财务指标和其他调整的更多信息,请参见下文“非IFRS财务指标”。

2 Vext has executed an asset purchase agreement (as amended from time to time, the "Asset Purchase Agreement"), together with other definitive agreements (together with the Asset Purchase Agreement, the "Definitive Agreements"), with the members of Big Perm's Dispensary Ohio, LLC ("Big Perm") to acquire from Big Perm two cannabis dispensaries located in Ohio, as well as all licenses and assets related to the business of such dispensaries, other than excluded assets, for cash consideration of $7.7 million, subject to adjustments in certain circumstances (the "Ohio Expansion Transaction"). Subject to receipt of required regulatory approvals and other customary conditions precedent, the Company expects that closing of the Ohio Expansion Transaction will occur in 2024.

2 Vext已与Big Perm's Dispensary Ohio, LLC ("Big Perm")的成员签订资产购买协议(不时修订的"资产购买协议"),连同其他明确协议(与资产购买协议一起,即"明确协议"),从Big Perm处收购在俄亥俄州的两家大麻店,以及与此类店铺相关的所有牌照和资产(除了排除资产),以770万美元的现金对价为代价,在某些情况下进行调整(即"俄亥俄州扩张交易")。根据获得所需监管批准和其他习惯性的先决条件,该公司预计2024年完成俄亥俄州扩张交易的交割。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发